X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cancer (5) 5
female (4) 4
humans (4) 4
index medicus (4) 4
male (4) 4
oncology (4) 4
aged (3) 3
carboplatin (3) 3
carcinoma, non-small-cell lung - drug therapy (3) 3
carcinoma, non-small-cell lung - mortality (3) 3
carcinoma, non-small-cell lung - pathology (3) 3
chemotherapy (3) 3
lung cancer, non-small cell (3) 3
lung neoplasms - drug therapy (3) 3
lung neoplasms - mortality (3) 3
lung neoplasms - pathology (3) 3
aged, 80 and over (2) 2
antineoplastic agents (2) 2
antineoplastic combined chemotherapy protocols (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
cancer therapies (2) 2
carboplatin - administration & dosage (2) 2
clinical trials (2) 2
deoxycytidine - administration & dosage (2) 2
deoxycytidine - analogs & derivatives (2) 2
drug administration schedule (2) 2
hematology, oncology and palliative medicine (2) 2
kaplan-meier estimate (2) 2
life sciences (2) 2
lung cancer (2) 2
middle aged (2) 2
neoplasms. tumors. oncology. including cancer and carcinogens (2) 2
oncology, experimental (2) 2
paclitaxel (2) 2
proportional hazards models (2) 2
radiation therapy (2) 2
research (2) 2
survival (2) 2
toxicity (2) 2
treatment outcome (2) 2
tumors (2) 2
[ sdv.can ] life sciences [q-bio]/cancer (1) 1
[sdv.imm]life sciences [q-bio]/immunology (1) 1
abridged index medicus (1) 1
adenocarcinoma (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - mortality (1) 1
adjuvants (1) 1
administration, oral (1) 1
adult (1) 1
age (1) 1
agents (1) 1
agriculture (1) 1
anemia (1) 1
angiogenesis inhibitors - administration & dosage (1) 1
angiogenesis inhibitors - adverse effects (1) 1
angiogenesis inhibitors - therapeutic use (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal - adverse effects (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antibodies, monoclonal, humanized (1) 1
antimitotic agents (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - therapeutic use (1) 1
bevacizumab (1) 1
biopsy (1) 1
cancer vaccine (1) 1
carboplatin - adverse effects (1) 1
carboplatin/paclitaxel (1) 1
carcinoma, non-small-cell lung (1) 1
carcinoma, non-small-cell lung - enzymology (1) 1
carcinoma, non-small-cell lung - genetics (1) 1
carcinoma, non-small-cell lung - surgery (1) 1
carcinoma, squamous cell (1) 1
carcinoma, squamous cell - drug therapy (1) 1
carcinoma, squamous cell - mortality (1) 1
care and treatment (1) 1
chi-square distribution (1) 1
cisplatin (1) 1
cisplatin - administration & dosage (1) 1
class-ii expression (1) 1
clinical grade (1) 1
combination (1) 1
comorbidity (1) 1
ct imaging (1) 1
cyberknife (1) 1
data processing (1) 1
deoxycytidine (1) 1
disease-free survival (1) 1
drug-related side effects and adverse reactions (1) 1
drugs (1) 1
efficacy (1) 1
epidermal growth factor receptors (1) 1
erlotinib (1) 1
erlotinib hydrochloride (1) 1
europe (1) 1
exanthema (1) 1
exons (1) 1
exosomes (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9796, pp. 1079 - 1088
Summary Background Platinum-based doublet chemotherapy is recommended to treat advanced non-small-cell lung cancer (NSCLC) in fit, non-elderly adults, but... 
Internal Medicine | SURVIVAL | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | INTERNATIONAL-SOCIETY | GERIATRIC ASSESSMENT | UNDERREPRESENTATION | OLDER | OUTCOMES | COMBINATION | AGE | COMORBIDITY | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Vinblastine - administration & dosage | Carboplatin - adverse effects | Carcinoma, Squamous Cell - mortality | Vinblastine - analogs & derivatives | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Paclitaxel - administration & dosage | Drug Administration Schedule | Deoxycytidine - administration & dosage | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Survival Rate | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Clinical trials | Chemotherapy | Radiation therapy | Cancer therapies | Adenocarcinoma | Vinblastine | Carcinoma, Non-Small-Cell Lung | Antineoplastic Agents | Antineoplastic Combined Chemotherapy Protocols | Lung Neoplasms | Carcinoma, Squamous Cell | Life Sciences | Deoxycytidine | Paclitaxel | Carboplatin | Cancer
Journal Article
by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer
Journal Article
Journal Article
Case Reports in Oncology, ISSN 1662-6575, 07/2014, Volume 7, Issue 2, pp. 422 - 425
Thymic epithelial tumors are rare and often occur somewhere local. Metastatic sites of thymic carcinomas (Masaoka-Koga stage IVb) are mostly seen in the lung,... 
Published: July 2014 | Extrathoracic metastasis | Thymoma | Pelvic metastasis | Thymic carcinoma | Positron emission tomography
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.